In Situ Hybridization: US Market Shares, Strategy, and Forecasts, 2018 to 2024

  • ID: 4480365
  • Report
  • Region: Global
  • 242 Pages
  • Wintergreen Research, Inc
1 of 5
The US Market for In Situ Hybridization at $4.3 Billion in 2017 and is Anticipated to Reach $7.8 Billion by 2024, with a CAGR of 7.8%

FEATURED COMPANIES

  • Abbott Laboratories
  • Advanced Cell Diagnostics
  • BioGenex Laboratories
  • Biotechne US
  • Exiqon A/S
  • Merck KGaA
  • MORE

In Situ Hybridization: Technology Evolves To Provide Better Management of Diagnoses for Cancer, Infectous Disease, Chromosonal Abnormalities, Inflamatory Disease

This 2018 study has 242 pages, 83 tables and figures. US markets are poised to achieve continuing growth as In Situ Hybridization is used in diagnostic situations to analyze single cells inside tissue. Managing single cell diagnostics in real time, encouraging collaborative business efforts. Lowering transaction management costs is a key benefit.

In situ hybridization (ISH) is a type of hybridization that uses a labeled complementary DNA, RNA or modified nucleic acids strand (i.e., probe) to localize a specific DNA or RNA sequence in a portion or section of tissue (in situ), or, if the tissue is small enough (e.g., plant seeds, Drosophila embryos), in the entire tissue (whole mount ISH), in cells, and in circulating tumor cells (CTCs).

Advances in RNA in situ hybridization transform molecular detection with morphological context enabling new applications. Scientists use RNA ISH to extract data dimensions. Immunohistochemistry (IHC) and RNA in situ Hybridization are widely used technologies sharing the unique capacity to analyze a marker at the single cell level while preserving the morphological context. In different situations, IHC and ISH are used in conjunction to validate data or provide complementary information.

In situ hybridization (ISH) is a powerful technique for localizing specific nucleic acid targets within fixed tissues and cells, allowing users to obtain temporal and spatial information about gene expression and genetic loci. While the basic workflow of ISH is similar to that of blot hybridizations—the nucleic acid probe is synthesized, labeled, purified, and annealed with the specific target—the difference is the greater amount of information gained by visualizing the results within the tissue.

The US market for In Situ Hybridization (ISH) at $4.3 billion in 2017 and is anticipated to reach $7.8 billion by 2024, with CAGR of 7.8% in the next five years (2017 to 2024). Increasing diagnosis and growing incidence & prevalence of cancer, technology advancements in therapeutics, increasing government initiatives globally are expected to drive the growth of the market in the coming years.

Key Topics:

  • In Situ Hybridization
  • Molecular Diagnostics
  • Cervical Cancer Stain
  • Fish Steps Reduction
  • Fluorescence In Situ
  • Hybridization (FISH)
  • In Situ Hybridization (ISH)
  • FISH Probe Kit
  • Cancer
  • Chromosonal Abnormalities
  • Infectious Diseases
  • Inflammatory Diseases
  • Fluorescence In Situ
  • Hybridization (FISH)
  • Chromogenic In Situ
  • Hybridization (CISH)
  • Human Genetic Tests
  • Microbial Tests
  • In Vitro Diagnostics
  • System for the Analysis of Solid Tumors
  • Hybridization Technique
  • Detection of Long Non
  • Coding DNA
  • Coding RNA
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Abbott Laboratories
  • Advanced Cell Diagnostics
  • BioGenex Laboratories
  • Biotechne US
  • Exiqon A/S
  • Merck KGaA
  • MORE

1. US In situ Hybridization Executive Summary
1.1 In Situ Hybridization (ISH)

2. United States In Situ Hybridization ISH Market Definition and Market Dynamics
2.1 US In situ Hybridization Market Overview
2.1.1 Antibody Challenges and Validation
2.2 Scope of In situ Hybridization in Inflammation
2.2.1 RNAscope® Applications

3. In-Situ Hybridization Market Shares and Market Forecasts
3.1 In-Situ Hybridization Market Driving Forces
3.1.1 Identification of Cytokines and their Cellular Origins
3.1.2 Detection of Long Non-Coding RNA (lncRNA) in Inflammatory Diseases
3.1.3 Role of Inflammatory Pathways During Carcinogenesis
3.1.4 Therapeutic Potential Of Secreted Proteins In Inflammatory Diseases
3.1.5 Dual ISH-IHC Detect Cytokines During Inflammatory Responses
3.2 In Situ Hybridization Market Shares
3.2.1 Roche
3.2.2 Abbott Molecular
3.2.3 Advanced Cell Diagnostics
3.2.4 PerkinElmer In Situ Hybridization Market Driving Forces
3.2.5 In Situ Hybridization Market Shares, Unit Shipments and Kit Shipments
3.3 In Situ Hybridization Market Forecasts
3.3.5 In Situ Hybridization Market Segments, Units and Kits, Dollars and Percent, US,
3.4 In situ Hybridization Market Segments
3.4.1 In Situ Hybridization Market Shares, Dollars, Worldwide, 2012 to 2017
3.4.2 Fluorescence (FISH) and Chromogenic (CISH) Detection
3.4.3 ISH Applications
3.4.4 Multiplex Fluorescence In Situ Hybridization (FISH)
3.4.5 Fluorescence In Situ Hybridization (FISH)
3.4.6 Cancer Drug Market
3.4.7 Chronic Lymphocytic Leukemia (CLL)
3.4.8 In-Situ Hybridization Cancer Diagnosis, Cytology, Infectious Disease Molecular Diagnostic
3.1.6 In Situ Hybridization Market Segments, Diagnostic Laboratories, Academic & Research Institutes, Contract Research Organizations, and Pharmaceutical & Biotechnology Companies
3.5 In-Situ Hybridization Pricing
3.5.1 miRCURY LNA miRNA Detection Probes
3.5.2 Price and Availability
3.6 In-Situ Hybridization Geographical Analysis

4. In-Situ Hybridization Research and Technology
4.1 Hybridization Technique

5. In-Situ Hybridization Company Profiles
5.1 Abbott Laboratories
5.1.1 Abbott Laboratories Market Categorization
5.1.2 In Situ Hybridization Product Category, Application and Specification
5.1.3 Abbott Laboratories Vysis Chronic Lymphocytic Leukemia (CLL) FISH Probe Kit (IVD)
5.1.4 Vysis CLL FISH Probe Kit Contents
5.1.5 Acupath Laboratories Test For Detecting Bladder Cancer Uses Probes from Abbott Molecular
5.1.6 Abbott Laboratories Barrett’s Esophagus FISH
5.1.7 Abbott Molecular Vysis CLL FISH Probe Kit -
5.1.8 Abbott Laboratories Revenue
5.1.9 Abbott Laboratories ThermoBrite System
5.1.10 Abbott Laboratories User Programmable Settings
5.1.11 Abbott Laboratories Vysis FISH Chromosome Search
5.1.12 Abbott Laboratories Molecular Diagnostics
5.1.13 Abbott Diagnostic Products
5.2 Acupath Laboratories
5.2.1 Acupath Laboratories Barrett’s Esophagus FISH
5.3 Agilent Technologies
5.3.1 Agilent CGH & CGH+SNP Microarrays
5.3.2 Agilent Technologies Revenue
5.3.3 Agilent Diagnostics and Genomics
5.4 Bio-Techne / ACD
5.4.1 Bio-Techne ACD RNAscope Widely Used In-Situ Hybridization Technique
5.4.2 Bio-Techne Revenue
5.4.3 Biotechne US Regional Analysis
5.4.4 Advanced Cell Diagnostics
5.5 F. Hoffmann-La Roche AG
5.5.1 Roche Gene Amplification by Fluorescence In Situ Hybridization
5.5.2 Roche Automated RNA isolation
5.5.3 Roche Fluorescence In Situ Hybridization (FISH)
5.5.4 Roche Agreement with Merck Millipore Sigma
5.5.5 Roche Immuno Diagnostics
5.5.6 F. Hoffmann-La Roche AG Revenue
5.5.7 Roche Buys Flatiron Health Leader In Oncology-Specific Electronic Health Record (EHR) Software
5.6 Danaher / Leica Biosystems Nussloch GmbH
5.6.1 Leica Biosystems Nussloch GmbH BOND IHC/ISH Instruments
5.6.2 Leica Biosystems Nussloch GmbH Revenue
5.6.3 Danaher Geographical Revenue
5.7 Thermo Fisher Scientific
5.7.1 Thermo Fisher Scientific Fluorescence In Situ Hybridization (FISH)
5.7.2 Chromogenic In Situ Hybridization (CISH)
5.7.3 Thermo Fisher Scientific Revenue
5.8 Merck KGaA
5.9 PerkinElmer
5.9.1 PerkinElmer Stain
5.9.2 Perkin Elmer Revenue
5.10 Qiagen / Exiqon A/S
5.10.1 Qiagen’s GeneReader NGS System
5.10.2 Polygenetic Mutations Drive Cancer
5.10.3 Qiagen Revenue
5.11 BioGenex Laboratories
5.11.1 BioGenex Fully-Automated Molecular Pathology Workstation
5.11.2 BioGenex Boosts Genome Research and Diagnostics - BioGenex US
5.11.3 BioGenex Antibodies for Cancer Diagnosis
5.11.4 BioGenex PMS2 CK5
5.11.5 eFISHiency System for the Analysis of Solid Tumors - BioGenex US
5.12 Bio SB
5.12.1 Bio SB Zytovision Molecular Diagnostics
5.13 Bio-Techne / Advanced Cell Diagnostics (ACD)

6. Summary and Conclusions
6.1 Analyze A Marker At The Single Cell Level
6.2 Advances in RNA In Situ Hybridization

7. Appendix A: List Of Nucleic Acid-Based Tests
7.1 List: Nucleic Acid-Based Tests Approved by US Center for Devices and Radiological Health
7.1.1 List of Human Genetic Tests
7.1.2 List of Microbial Tests
7.2 In Vitro Diagnostics

8. The Publisher
8.1 Research Methodology
8.2 Research Process
8.3 Market Research Study
8.4 Research Global Market Intelligence Company

List of Figures
Figure 1. In Situ Hybridization Market Shares, Dollars, US, 2016 and 2017
Figure 2. In Situ Hybridization Market Driving Forces
Figure 3. In Situ Hybridization Market Shares, Unit Shipments and Kit Shipments, Units and Dollars, US, 2017
Figure 4. In Situ Hybridization Market Shares, $ per Unit and $ per Kit, Dollars and Percent, US, 2017
Figure 5. In Situ Hybridization Market Segments, Unit Shipments and Kit Shipments, Units and Dollars, US, 2017
Figure 6. In Situ Hybridization Market Segments, $ per Unit and $ per Kit, Dollars and Percent, US, 2017
Figure 7. In Situ Hybridization Market Shares, Dollars, Worldwide, 2012 to 2017
Figure 8. In Situ Hybridization Market Segments, Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH), US, 2012 to 2017
Figure 9. In Situ Hybridization Market Segments, Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH), US, 2017 to 2024
Figure 10. Thermo Fisher Scientific Characteristics of In Situ Hybridization Methods
Figure 11. Diagnostics Growth
Figure 12. In Situ Hybridization Market Segments, Cancer, Chromosonal Abnormalities, Infectious Diseases, Dollars, US, 2012 to 2017
Figure 13. In Situ Hybridization Market Segments, Cancer, Chromosonal Abnormalities, Infectious Diseases, Dollars, US, 2017 to 2024
Figure 14. In Situ Hybridization Market Segments, Cancer, Chromosonal Abnormalities, Infectious Diseases, Percent, US, 2017 to 2024
Figure 15. In Situ Hybridization Market Segments, Cancer, Chromosonal Abnormalities, Infectious Diseases, Percent, US, 2012 to 2017
Figure 16. In Situ Hybridization Market Segments, Diagnostic Laboratories, Academic & Research Institutes, Contract Research Organizations, and Pharmaceutical & Biotechnology Companies, Dollars, US, 2012 to 2017
Figure 17. In Situ Hybridization Market Segments, Diagnostic Laboratories, Academic & Research Institutes, Contract Research Organizations, and Pharmaceutical & Biotechnology Companies, Dollars, US, 2017 to 2024
Figure 18. In Situ Hybridization Market Segments, Diagnostic Laboratories, Academic & Research Institutes, Contract Research Organizations, and Pharmaceutical & Biotechnology Companies, Percent, US, 2012 to 2017
Figure 19. In Situ Hybridization Market Segments, Diagnostic Laboratories, Academic & Research Institutes, Contract Research Organizations, and Pharmaceutical & Biotechnology Companies, Percent, US, 2017 to 2024
Figure 20. 575 Million People with Autoimmune Disease
Figure 21. PerkinElmer Assays for Autoimmune Disease
Figure 22. PerkinElmer Diagnostics
Figure 23. PerkinElmer In Situ Hybridization
Figure 24. In Situ Hybridization Regional Analysis, US: West, Rocky Mountain, Southwest, Midwest, South, Middle Atlantic, New York and New England, Percent, 2012 - 2017
Figure 25. In Situ Hybridization Regional Analysis, US: West, Rocky Mountain, Southwest, Midwest, South, Middle Atlantic, New York and New England, Percent, 2017 - 2024
Figure 26. Abbott Laboratories Vysis CLL FISH Probe Kit Probe Info
Figure 27. Abbott Laboratories Vysis CLL FISH Probe Kit Contents
Figure 28. Abbott Laboratories Vysis CLL FISH Probe Kit includes LSI
Figure 29. Abbott Vysis CLL FISH Probe Kit
Figure 30. Abbott Laboratories Segment Sales, 2017
Figure 31. Abbott Segment Sales 2015-2017
Figure 32. Abbott Geographical Revenue
Figure 33. Abbott Laboratories ThermoBrite System
Figure 34. Abbott Laboratories ThermoBrite System Functions
Figure 35. Abbott Laboratories Molecular Testing
Figure 36. Abbott Diagnostic Product Target Markets
Figure 37. Abbott Diagnostic Principal Products
Figure 38. In Situ Hybridization Detection System: Agilent Product Area: Standard Nucleic Acid Detection System
Figure 39. PNA ISH Detection Kit Product Area: PNA Probes & Detection System
Figure 40. Roche RNA Isolation Kit
Figure 41. Merck MilliporeSigma and Sigma-Aldrich and Roche Offerings
Figure 42. Key points of the Roche Merc agreement include:
Figure 43. Roche Immuno Diagnostics DISCOVERY XT
Figure 44. Roche DISCOVERY XT Research Instrument Functions
Figure 45. F. Hoffmann-La Roche AG Sales
Figure 46. Roche by the Metrics
Figure 47. F. Hoffmann-La Roche AG Pharmaceutical Sales
Figure 48. Danaher Brands
Figure 49. Leica Biosystems Bond III Technical Specifications
Figure 50. Leica Biosystems Nussloch GmbH BOND IHC/ISH Instruments
Figure 51. Leica SCN400 Slide Scanner Features
Figure 52. Leica BOND Ready-To-Use Antibodies (No Mixing, Titration Or Dilution)
Figure 53. Leica Biosystems
Figure 54. Danaher Segment Revenue
Figure 55. Thermo Fisher Scientific Fluorescence In Situ Hybridization (FISH) Positioning
Figure 56. Thermo Fisher Scientific Fluorescence In Situ Hybridization (FISH) In Situ Hybridization (ISH) Technologies
Figure 57. Thermo Fisher Scientific Characteristics of In Situ Hybridization Methods
Figure 58. 5.7.1 Thermo Fisher Scientific EVOS Cell Imaging Systems
Figure 59. Thermo Fisher Scientific Fluorescence Systems
Figure 60. Thermo Fisher Scientific Cell Analysis
Figure 61. Thermo Fisher Scientific Imaging Portfolio Components
Figure 62. Thermo Fisher Scientific Revenue
Figure 63. PerkinElmer In Situ Hybridization
Figure 64. PerkinElmer In Situ Hybridization
Figure 65. PerkinElmer In Situ Hybridization
Figure 66. PerkinElmer Financials at a Glance
Figure 67. PerkinElmer Diagnostics Revenue
Figure 68. PerkinElmer in situ hybridization Expanding Diagnostics Market Reach and Global Impact
Figure 69. PerkinElmer Diagnostics
Figure 70. PerkinElmer Stain
Figure 71. Perkin Elmer Revenue
Figure 72. PerkinElmer offers Ultra-Sensitive And Specific Mirna Detection By In Situ Hybridization (ISH) Functions
Figure 73. miRCURY LNA miRNA Detection Probes
Figure 74. BioGenex Performance Systems
Figure 75. BioGenex Product Areas
Figure 76. BioGenex Performance Systems / BioGenex Flagship Products
Figure 77. BioGenex Customers
Figure 78. Figure: Colon Carcinoma stained with PMS2 (clone EP51),Staining in FFPE tisues, using DAB chromogen and BioGenex Polymer-HRP Detection System.
Figure 79. BioGenex Cervical Cancer Stained with Anti-Human CK-5 (clone EP24),Staining in FFPE Tissues, Using DAB Chromogen and Polymer-HRP Detection System
Figure 80. BioGenex Fish Steps Reduction
Figure 81. BioGenex eFISHiency System Reduces Hands-On Processing Time To 30 Minutes
Figure 82. Bio SB Zytovision Molecular Diagnostics
Figure 83. Bio-Techne / ACD

Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Abbott Laboratories
  • Acupath Laboratories
  • Advanced Cell Diagnostics
  • Agilent Technologies
  • Bio SB Zytovision Molecular Diagnostics
  • Bio-Techne
  • BioGenex Laboratories
  • Biotechne US
  • Chromogenic In Situ Hybridization (CISH)
  • Danaher
  • Exiqon A/S
  • F. Hoffmann-La Roche AG
  • Leica Biosystems Nussloch GmbH
  • Merck KGaA
  • PerkinElmer
  • Qiagen
  • Roche Immuno Diagnostics
  • Thermo Fisher Scientific
  • Vysis
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll